BioCardia, Inc. announced that following a recent share sale via an "At The Market" offering agreement with H.C. Wainwright & Co., the company has regained compliance with Nasdaq's minimum $2.5 million stockholders' equity requirement. Between April 1, 2026, and June 5, 2026, the company sold 4,004,330 shares at an average price of $1.27, generating $4.9 million in net proceeds. BioCardia, Inc. is a biotechnology company focused on developing cardiovascular therapies.
